emocha’s  $6.2 million Series A raise was recently featured in Fierce Healthcare, and emocha CEO Sebastian Seiguer spoke about the continuing challenge of medication adherence. “I find it absolutely mind-blowing that medication non-adherence would continue to exist as dramatically as it does,” Seiguer said. emocha’s program measures true, dose-by-dose adherence, rather than often-used metrics like refill rates. Seiguer advocates for a more precise measure of adherence.  “In some cases, patients should refill their medication—that’s a great thing,” Seiguer said. “But the amount of confusion, the number of medication errors that happen, it’s unbelievable to me. It’s an urgent problem.”

Read the full article in Fierce Healthcare